|Budget Amount *help
¥6,000,000 (Direct Cost : ¥6,000,000)
Fiscal Year 1993 : ¥1,000,000 (Direct Cost : ¥1,000,000)
Fiscal Year 1992 : ¥1,500,000 (Direct Cost : ¥1,500,000)
Fiscal Year 1991 : ¥3,500,000 (Direct Cost : ¥3,500,000)
Aims ; To create human parvovirus B19 antigens.
Methods ; Productions of virus particles in cell cultures, of antigenic protein by gene engineering, and of antigenic peptides by synthesis.
Results ; Among the hematopoietic cell lines ; K562, KU-812-F, RO 10 and JK-1, and mononuclear cells in umbilical cord blood and in venous blood (rest of the component blood transfusion), virus grew better in mononuclear cells from umbilical cord blood, though less than in those from bone marrow cells. Virus protein in e.coli was hardly produced by almost full length of the genome DNA cut bilateral ends with a restriction enzyme EcoR 1. Novel five synthetic peptides were showed clear and specific antigenicity by indirect ELISA test, better than two, which were 3293 - 3364 (reported by Fridell), 4106- 4156 (reported by Sato). Gene positions of those were 2912 - 2956, 2892 - 2971 in the region of VP1, 4016 - 4081, 4142 - 4189, and 4127 - 4201 in VP2. The full paper is in preparation.